News
Market and company headlines
BNTXAll
Loading
05:00Yesterday1 Story
08:00-11:00Oct 252 Stories
BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?
BioNTech (NasdaqGS:BNTX) just expanded its oncology pipeline by announcing new Phase 2 data for pumitamig plus docetaxel in metastatic non small cell lung cancer, alongside a new Phase 3 collaboration in triple negative breast cancer. Despite a steady flow of oncology updates in October, BioNTech’s share price has moved unevenly, with a 7-day share price return of 0.46% sitting against a 30-day decline of 10.56% and a 1-year total shareholder return decline of 16.61%. This combination points...
BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach
BioNTech (NasdaqGS:BNTX) and Gilead Sciences agreed to a clinical trial collaboration to study pumitamig with sacituzumab govitecan in first-line metastatic triple-negative breast cancer. The partners plan to adapt an existing global Phase 3 trial of pumitamig so that it reflects current clinical standards for treating metastatic triple-negative breast cancer. This will be the first worldwide Phase 3 study to test pumitamig in combination with an antibody-drug conjugate, marking a new step...
03:00Oct 251 Story
00:00-03:00Oct 222 Stories
BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer
Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ("BMS").ROSETTA Breast-01 is a
BioNTech (BNTX) Stock May Be Fully Valued Despite Fresh Oncology Data Preview
BioNTech has seen its share price move around in recent years, and with the focus increasingly on its oncology pipeline, the key question now is whether the current valuation is still aligned with the revenue base behind it. For anyone watching the stock, the issue is less about headlines and more about what today’s price implies for the business that generates those sales. Over the past 5 years the stock has fallen 66.9%. This puts the spotlight squarely on whether the market is now valuing...
06:00Oct 201 Story
02:00-07:00Oct 192 Stories
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic non-small cell lung cancer following prior immunotherapy plus chemotherapy Global Phase 2 data for pumitamig plus elfetabart drozuntecan, a B7-H3-targeting antibody-drug conjugate, expand the body of evidence for this novel-novel combination in multiple advanced solid tumors Upda
BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic
04:00Oct 171 Story
04:00Oct 141 Story
17:00-00:00Oct 132 Stories
BioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?
In October 2026, BioNTech reported that its AHEAD-MERIT Phase 2/3 trial of mRNA cancer candidate BNT113 plus pembrolizumab in advanced HPV-linked head and neck cancer did not meet its first primary endpoint of improving progression-free survival versus pembrolizumab alone, although the study continues to assess overall survival. This outcome highlights both the scientific difficulty of translating mRNA technology into effective solid-tumor therapies and the clinical importance now placed on...
What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?
BioNTech (NasdaqGS:BNTX) reported that its Phase 2/3 trial of BNT113 in head and neck cancer did not meet the progression-free survival primary endpoint. The company is keeping the trial active to continue evaluating overall survival as a key secondary outcome measure. BNT113 is part of BioNTech's mRNA-based oncology portfolio that targets HPV16-positive head and neck tumors. To put this update on BioNTech in context, consider reviewing other healthcare and AI-focused stocks via 33...
08:00Oct 132 Stories
BioNTech stock falls after cancer trial misses key endpoint
Investing.com --BioNTech (NASDAQ: BNTX) shares fell 5% on Tuesday after the company announced that a mid-to-late-stage clinical trial for its experimental mRNA cancer drug, BNT113, missed its first major goal.
Why Is BioNTech Stock Falling Tuesday?
BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.
11:00Oct 11 Story
11:00Sep 301 Story
03:00-11:00Sep 292 Stories
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
Wall Street Breakfast Podcast: Federal Boost For Navitas
A new U.S. government award has Navitas shares surging. After a string of acquisitions, Lilly is hunting for its next big bet. A judge keeps a high-stakes mRNA patent battle alive.
08:00Sep 281 Story
21:00Sep 261 Story
16:00Sep 241 Story
05:00-10:00Sep 172 Stories
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.
Summit Therapeutics: It's Okay Not To Have An Answer
Summit Therapeutics' ivonescimab data looks promising but uncertain amid dilution, royalties and catalysts. See why I rate SMMT stock a Hold right now.
15:00-19:00Sep 162 Stories
Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?
BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today’s valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current...
BioNTech (BNTX) Posts Strong Lung Cancer Data, Is It A Bargain?
BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that...
10:00Sep 151 Story
04:00-11:00Sep 142 Stories
Why Is BioNTech Stock Gaining Monday?
On Monday, BioNTech SE (NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lun
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this
13:00Sep 11 Story
04:00-13:00Aug 312 Stories
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.
14:00-22:00Aug 283 Stories
BioNTech (BNTX) Ended A Phase 2 Colorectal Cancer Trial
BioNTech (NasdaqGS:BNTX) halted a Phase 2 trial of its individualized mRNA immunotherapy in colorectal cancer after an independent Data Safety Monitoring Board recommended termination for futility. The board cited a numerical imbalance in overall survival between treatment arms as a key factor in its decision. The discontinued study involved BioNTech's collaboration with Genentech and targeted colorectal cancer, an area described as having significant unmet medical need. This is the first...
BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win
BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.
01:00-05:00Aug 202 Stories
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.
BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy Approaches
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in
10:00-20:00Aug 192 Stories
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.
Let's uncover which stocks are experiencing notable gaps during today's session.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
